Yelena Janjigian
耶莱娜·扬吉江
MD
Chief, Gastrointestinal Oncology Service胃肠肿瘤服务主任
👥Biography 个人简介
Dr. Yelena Janjigian leads GI Oncology at MSKCC and is a global authority on gastric cancer. She spearheaded the CheckMate 649 trial, establishing nivolumab plus chemotherapy as the first-line global standard for HER2-negative advanced gastric cancer, transforming care worldwide.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
First-Line Nivolumab in Gastric Cancer
Led CheckMate 649, the landmark trial that established nivolumab plus FOLFOX/XELOX as standard first-line therapy for advanced gastric/GEJ/esophageal adenocarcinoma, now adopted globally.
HER2-Targeted Combinations
Developed novel HER2-directed immunotherapy combinations and defined resistance mechanisms to HER2 blockade in gastric cancer, informing next-generation treatment strategies.
Representative Works 代表性著作
Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastro-oesophageal junction cancer/oesophageal adenocarcinoma (CheckMate 649)
The Lancet (2021)
Practice-changing phase III trial showing nivolumab-chemotherapy prolonged OS in PD-L1 CPS≥5 and all-randomized advanced gastric cancer populations.
Pembrolizumab and trastuzumab in HER2-positive, advanced gastric or gastro-oesophageal junction cancer: an open-label, single arm, phase 2 trial
The Lancet Oncology (2020)
Showed anti-PD-1 plus trastuzumab was active in HER2-positive gastric cancer, supporting triplet regimen development.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Zev Wainberg
UCLA Health / David Geffen School of Medicine
Cathy Eng
Vanderbilt-Ingram Cancer Center
Daniel Coit
Memorial Sloan Kettering Cancer Center
Johanna Bendell
Sarah Cannon Research Institute
关注 耶莱娜·扬吉江 的研究动态
Follow Yelena Janjigian's research updates
留下邮箱，当我们发布与 Yelena Janjigian（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment